Journal
MOLECULAR THERAPY
Volume 18, Issue 4, Pages 692-699Publisher
CELL PRESS
DOI: 10.1038/mt.2009.318
Keywords
-
Categories
Funding
- NCDGG [1U19 CA113341-01]
- American Cancer Society (ACS)
- National Cancer Institute SPORE in Cervical Cancer [P50 CA098252, 1 RO1 CA114425-01]
- NATIONAL CANCER INSTITUTE [U19CA113341, R01CA114425, P50CA098252] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cancer therapy using oncolytic viruses represents a promising new approach for controlling ovarian cancer. In this study, we have circumvented the limitation of repeated vaccination by employing different virus vectors, Semliki Forest Virus (SFV) and vaccinia virus (VV) for boosting the immune response. We found that infection of tumor-bearing mice with VV followed by infection with SFV or vice versa leads to enhanced antitumor effects against murine ovarian surface epithelial carcinoma (MOSEC) tumors. Furthermore, infection with VV-ovalbumin (OVA) followed by infection with SFV-OVA or vice versa was found to lead to enhanced OVA-specific CD8(+) T-cell immune responses. In addition, we found that infection with SFV-OVA followed by infection with VV-OVA leads to enhanced antitumor effects in vivo and enhanced tumor killing in vitro through a combination of viral oncolysis and antigen-specific immunity. The clinical implications of this study are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available